Value Analysis

The developed healthcare systems in the German-speaking countries force manufacturers to produce evidence that demonstrates the (added) value of their innovative technology. Manufacturers are more and more obliged to supply data on patient benefit and, increasingly, health economic information.

Our job is to advise our clients as to what kind of information they should have available, when and for whom. Once the strategy and the time frame are agreed, we help our clients hands-on in creating the required value as soon and as cost-effectively as possible. We offer flexible and on-going services, including:


Value Dossier Development

In order to prepare for the reimbursement and market requirements it is often advisable to develop a generic Value Dossier in German, which can be customized to meet the needs of different target groups. The dossier may cover different sections such as:

  • General information about the product / therapy
  • Clinical evidence  
  • Health economic information
  • Value proposition


Business Case / Profitability Analysis

We support our clients to develop a business case that demonstrates outcomes and cost-effectiveness of their novel technology. It is vital to choose an appropriate perspective that typically may be either a hospital/doctor or a payer/society view. This type of health economic data can be considered a solid basis for reimbursement and marketing activities and could be a very convincing argument for a quick introduction into the German healthcare market..


Availability of Evidence Analysis, Searches and Reviews

As an opportunity to speed up the introduction of new procedures into the reimbursement system, we offer to assess the quality of the available information and data with respect to benefit, medical necessity and economic rationale of your devices and procedures. Some of the services we offer include: 

  • Gap analysis and evidence development strategy, as an aid in determining how to move forward with evidence development where data is lacking (critique of existing protocols or input into new study designs)
  • Internal HTA / benefit assessment to identify what relevant authorities such as the IQWiG in Germany would expect to see at the point at which they undertake a full systematic review
  • "Quick" literature scans assessing and identifying key items of the evidence base for the device / technology under scrutiny
  • Literature search and systematic review of the published evidence on a technology. Review and grading of both the quantity and quality of the available studies according to accepted scientific methodologies (e.g. G-BA & IQWiG).

Developement of Integrated Care projects

Healthcare organization and financing in Germany is more and more focussing on selective contracting rather than on standard  framework regulations and contracts (such as the current G-DRG system for hospital care).  Forms of direct contracts between payers (sickness funds) and providers (e.g. hospitals, doctors) include Integrated Care concepts. As an interim option and/or partial solution in order to obtain reimbursement in conjunction with novel healthcare technologies it can be worthwhile to develop concepts and contracts in this area.